Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era, Blood, vol.117, pp.26-38, 2011. ,
Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain, Immunol Rev, vol.228, pp.58-73, 2009. ,
, Pediatrics, vol.9, pp.722-730, 1952.
Targeting pathological B cell receptor signalling in lymphoid malignancies, Nat Rev Drug Discov, vol.12, pp.229-272, 2013. ,
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is effi cacious in models of autoimmune disease and B-cell malignancy, Proc Natl Acad Sci U S A, vol.107, pp.13075-80, 2010. ,
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma, N Engl J Med, vol.369, pp.507-523, 2013. ,
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia, N Engl J Med, vol.369, pp.32-42, 2013. ,
, Ibrutinib approved for mantle cell lymphoma, Cancer Discov, vol.4, p.1, 2014.
Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group, Blood, vol.111, pp.2385-2392, 2008. ,
Specifi c inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts, Mol Cancer Ther, vol.3, pp.1427-1465, 2004. ,
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma, Blood, vol.119, pp.4597-607, 2012. ,
, Palbociclib Ups PFS in HER2?/ER+ breast cancer, Cancer Discov, vol.4, pp.624-629, 2014.
A novel orally active small molecule potently induces G 1 arrest in primary myeloma cells and prevents tumor growth by specifi c inhibition of cyclin-dependent kinase 4/6, Cancer Res, vol.66, pp.7661-7668, 2006. ,
Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4, Blood, vol.120, pp.1095-106, 2012. ,
A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model, Cancer Res, vol.68, pp.5519-5542, 2008. ,
Induction of prolonged early G 1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kdelta inhibition through PIK3IP1, Cell Cycle, vol.12, pp.1892-900, 2013. ,
Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specifi c gene expression profi les in mantle cell lymphoma, Proc Natl Acad Sci, vol.103, pp.2352-2359, 2006. ,
The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma, Blood, vol.121, pp.3161-3165, 2013. ,
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma, Proc Natl Acad Sci U S A, vol.110, pp.18250-18255, 2013. ,
Pharmacological and genomic profi ling identifi es NF-kappaBtargeted treatment strategies for mantle cell lymphoma, Nat Med, vol.20, pp.87-92, 2014. ,
The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells, Blood, vol.123, pp.2988-96, 2014. ,
mTrs130 is a component of a mammalian TRAPPII complex, a Rab1 GEF that binds to COPI-coated vesicles, Mol Biol Cell, vol.20, pp.4205-4220, 2009. ,
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib, N Engl J Med, vol.370, pp.2286-94, 2014. ,
P110delta, a novel phosphoinositide 3-kinase in leukocytes, Proc Natl Acad Sci U S A, vol.94, pp.4330-4335, 1997. ,
Egress of CD19+CD5+ cells into peripheral blood following treatment with the BTK inhibitor ibrutinib in mantle cell lymphoma patients, Blood, vol.122, pp.2412-2436, 2013. ,
PI3K is negatively regulated by PIK3IP1, a novel p110 interacting protein, Biochem Biophys Res Commun, vol.358, pp.66-72, 2007. ,
Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha, Science, vol.283, pp.393-400, 1999. ,
PI3 kinase signals BCR-dependent mature B cell survival, Cell, vol.139, pp.573-86, 2009. ,
American Association for Cancer cancerdiscovery.aacrjournals.org Downloaded from antagonizing intrinsic and extrinsic cellular survival signals, Blood, vol.116, pp.2078-88, 2010. ,
The phosphoinositide 3?-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia, Blood, vol.118, pp.3603-3615, 2011. ,
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability, Blood, vol.117, pp.591-595, 2011. ,
BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110alpha and p110delta activities in tumor cell lines and xenograft models, Mol Cancer Ther, vol.12, pp.2319-2349, 2013. ,
The identifi cation of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer, J Med Chem, vol.51, pp.5522-5554, 2008. ,
Relapse-specifi c mutations in NT5C2 in childhood acute lymphoblastic leukemia, Nat Genet, vol.45, pp.290-294, 2013. ,
Uniparental disomies, homozygous deletions, amplifi cations, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profi ling, Blood, vol.113, pp.3059-69, 2009. ,
MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma, Nat Immunol, vol.14, pp.1084-92, 2013. ,
What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway, Cancer Discov, vol.3, pp.1345-54, 2013. ,
Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus, Nature, vol.508, pp.541-546, 2014. ,
A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2, J Exp Med, vol.184, pp.31-40, 1996. ,